Cancer Generics: Recent Approvals by USFDA
According to the National Cancer Institute’s estimates, nearly 142,820 people would be diagnosed with and 50,830 would die of cancer of the colon and rectum in 2013. On the other hand, it is estimated that 232,340 women would be diagnosed with and 39,620 women would die of cancer of the breast in 2013. Moving in the same lines, USFDA approved the first generic version of Xeloda (capecitabine), an oral chemotherapy pill used to treat cancer of the colon or rectum...
View full press release